Osimertinib after surgery to stop leftover lung spots
Treatments studied
Part of Cancer clinical trials.
This study tests whether osimertinib can prevent remaining abnormal lung spots (called ground-glass nodules) from growing after surgery. It is for people with lung cancer caused by specific EGFR gene changes (L858R or exon 19 deletion).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must agree to the study after being told what it involves (informed consent).
- You must be 30 to 75 years old and have lung adenocarcinoma confirmed by pathology (lab testing of tissue).
- Your lung scan must show one or more remaining ground-glass nodules in a different lung area (at least one other lobe).
- Your removed lung tumor must have an EGFR mutation limited to either L858R or exon 19 deletion.
- You must have had complete surgery for the main tumor and recover without major problems; your overall health score must be good (WHO 0–1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies osimertinib, a targeted medicine, after surgery to help stop lung cancer from growing or spreading. It’s for people with an early lung cancer that has EGFR mutations and leftover “ground-glass” lung spots in another area.
This trial tests osimertinib (a targeted pill) given after surgery to help prevent early-stage lung cancer from coming back. It’s for people with fully removed, high-risk stage I non-small cell lung cancer that has specific EGFR gene changes.
This study tests whether a targeted therapy pill called osimertinib can work for people whose non-small cell lung cancer came back after they had surgery and completed a course of adjuvant EGFR TKI therapy (like gefitinib or erlotinib). If your cancer has an EGFR mutation and you meet the other health criteria, this trial may offer an additional treatment option.
This trial tests whether adding targeted radiation or surgery to your regular osimertinib treatment can better control any remaining spots of lung cancer. It is for people with a specific EGFR mutation whose cancer has shrunk but left a few active sites.
This trial tests whether removing the main lung tumor with surgery after 12 weeks of osimertinib (a targeted pill) helps control cancer better than osimertinib alone, for people with advanced non-small cell lung cancer that has an EGFR mutation and limited spread.
This trial tests a new combination of the drug osimertinib with chemotherapy for people whose lung cancer has returned after they took osimertinib alone following surgery. It aims to see if this combined approach helps control the cancer better.
Hear when a new Lung Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.